medigraphic.com
ISSN 0035-0052 (Impreso)

2015, Número 2

<< Anterior

Rev Mex Pediatr 2015; 82 (2)


Manejo por drogas adictivas y tóxicos letales en Pediatría

Pinacho-Velázquez JL

Idioma: Español
Referencias bibliográficas: 39
Paginas: 71-79
Archivo PDF: 224.80 Kb.


RESUMEN

Los adolescentes y adultos jóvenes representan el grupo más vulnerable en el mercado de estimulantes: desde los cigarros hasta las metanfetaminas. En los últimos 10 años se ha incrementado el número de personas que acuden a los servicios de salud con antecedente de intoxicación o abuso de drogas adictivas o de tóxicos letales. En este artículo de revisión se describen las características de este tipo de pacientes, así como la forma de manejarlos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Hazinsky MF. Toxicology. In: Hazinsky MF, editor. PALS Provider Manual. Salem, Oregon, EUA: American Heart Association and American Academy of Paediatrics; 2012. pp. 305-319.

  2. Encuesta Nacional de Adicciones del 2011. Disponible en: www.conacid.salud.gob.mx/pdfs/ENA_2011_drogas_ilicitas_.pdf

  3. Beebe DK, Walley E. Smokable methamphetamine (“ice”): an old drug in a different form. Am Fam Physician. 1995; 51: 449-453.

  4. Callaway CW, Clark RF. Hyperthermia in psychostimulant overdose. Ann Emerg Med. 1994; 24: 68-76.

  5. Jones AL, Jarvie DR, McDermid G, Proudfoot AT. Hepatocellular damage following amphetamine intoxication. J Toxicol Clin Toxicol. 1994; 32: 435-444.

  6. Jorens PG, Heytens L, Demey HE, Andries S, Ricaurte GA, Bossaert L et al. Acute poisoning with amphetamines (MDEA) and heroin: antagonistic effects between the two drugs. Intensive Care Med. 1996; 22: 456-459.

  7. Mithoefer M, Jerome L, Doblin R. MDMA “ectasy” and neurotoxicity. Science. 2003; 300: 1504-1505.

  8. National Institute on Drug abuse, metanfetamina 2005, Available in: http://www.nida.nih.gov/infofacts/Methamphetamine-Sp.html

  9. Hoffman RS, Henry GC, Howland MA, Weisman RS, Weil L, Goldfrank LR. Association between life-threatening cocaine toxicity and plasmacholinesterase activity. Ann Emerg Med. 1992; 21: 247-253.

  10. Hoffman RS, Morasco R, Goldfrank LR. Administration of purified humanplasma cholinesterase protects against cocaine toxicity in mice. J Toxicol Clin Toxicol. 1996; 34: 259-266.

  11. Marcovigi P, Leoni S, Calbi G, Valtancoli E, Granata A, Gudenzi P et al. Acute cocaine poisoning in a body packer. Minerva Anestesiol. 1995; 61: 109-112.

  12. Aldrighetti L, Graci C, Paganelli M, Vercesi M, Catena M, Ferla G. Intestinal occlusion in cocaine-packet ingestion. Minerva Chir. 1993; 48: 1233-1237.

  13. Mueller PD, Benowitz NL, Olson KR. Cocaine. Emerg Med Clin North Am. 1990; 8: 481-493.

  14. Katz AA, Hoffman RS, Silverman RA. Phenytoin toxicity from smoking crack cocaine adulterated with phenytoin. Ann Emerg Med. 1993; 22: 1485-1487.

  15. Nogue S, Sanz P, Munne P, de la Torre R. Acute scopolamine poisoning after sniffing adulterated cocaine. Drug Alcohol Depend. 1991; 27: 115-116.

  16. Insley BM, Grufferman S, Ayliffe HE. Thallium poisoning in cocaine abusers. Am J Emerg Med. 1986; 4: 545-548.

  17. Stevens DC, Campbell JP, Carter JE, Watson WA. Acid-base abnormalities associated with cocaine toxicity in emergency department patients. J Toxicol Clin Toxicol. 1994; 32: 31-39.

  18. López MG. El niño intoxicado. En: Menabrito TJ. Urgencias. Temas de Pediatría Asociación Mexicana de Pediatría. McGraw Hill Interamericana México 1997. pp. 135-159.

  19. Lange RA, Cigarroa RG, Yancy CW, Willard JE, Popma JJ, Sills MN, et al. Cocain-induced coronary-artery vasoconstriction. N Eng J Med. 1989; 321: 1557-1562.

  20. Instituto Nacional de Abuso de Drogas. Serie de reportes de investigación Cocaína abuso y adicción 2005. Disponible en: http://www.drugabuse.gov/ResearchReports/Cocaina/Cocaina.html

  21. Farrar HC, James LP, Characteristics of pediatrics admissions for cyclic antidepressant poisoning. Am J Emerg Med. 1999; 17: 495-496.

  22. Hulten BA, Heath A. Clinical aspects of tricyclic antidepressant poisoning. Acta Med Scand. 1982; 213: 275-279.

  23. Rosenbaum TG, Kou M. Are one or two dangerous? Tricyclic antidepressant exposure in toddlers. J Emerg Med. 2005; 28: 169-174.

  24. Seger DL, Hantsch C, Zavoral T, Wrenn K. Variability of recommendations for serum alkalinization in tricyclic antidepressant overdose: a survey of U.S. Poison Center medical directors. J Toxicol Clin Toxicol. 2003; 41: 331-338.

  25. Thanacoody HK, Thomas SH. Tricyclic antidepressant poisoning: cardiovascular toxicity. Toxicol Rev. 2005; 24: 205-214.

  26. Ashraf M, Chaudhary K, Nelson J, Thompson W. Massive overdose of sustained-release verapamil: a case report and review of literature. Am J Med Sci. 1995; 310: 258-263.

  27. Goldfrank’s L. Toxicologic emergencies. Seventh ed., Editorial McGraw-Hill. 2002.

  28. Brayer AF, Wax P. Accidental ingestion of sustained release calcium channel blockers in children. Vet Hum Toxicol. 1998; 40: 104-106.

  29. Ioulios P, Charalampos M, Efrossini T. The spectrum of cutaneous reactions associated with calcium antagonists: a review of the literature and the possible etiopathogenic mechanisms. Dermatol Online J. 2003; 9: 6.

  30. Katz AM. Calcium channel diversity in the cardiovascular system. J Am Coll Cardiol. 1996; 28: 522-529.

  31. Ashraf M, Chaudhary K, Nelson J, Thompson W. Massive overdose of sustained-release verapamil: a case report and review of literature. Am J Med Sci. 1995; 310: 258-263.

  32. Barrow PM, Houston PL, Wong DT. Overdose of sustained-release verapamil. Br J Anaesth. 1994; 72: 361-365.

  33. Belson MG, Gorman SE, Sullivan K, Geller RJ. Calcium channel blocker ingestions in children. Am J Emerg Med. 2000; 18: 581-586.

  34. Taboulet P, Cariou A, Berdeaux A, Bismuth C. Pathophysiology and management of self-poisoning with beta-blockers. J Toxicol Clin Toxicol. 1993; 31: 531-551.

  35. DeWitt CR, Waksman JC. Pharmacology, pathophysiology and management of calcium channel blocker and beta-blocker toxicity. Toxicol Rev. 2004; 23: 223-238.

  36. Love JN. Beta-blocker toxicity: a clinical diagnosis. Am J Emerg Med. 1994; 12: 356-357.

  37. Love JN1, Howell JM, Litovitz TL, Klein-Schwartz W. Acute beta blocker overdose: factors associated with the development of cardiovascular morbidity. J Toxicol Clin Toxicol. 2000; 38: 275-281.

  38. Love JN1, Litovitz TL, Howell JM, Clancy C.Characterization of fatal beta blocker ingestion: a review of the American Association of Poison Control Centers data from 1985 to 1995. J Toxicol Clin Toxicol. 1997; 35: 353-359.

  39. Mégarbane B, Karyo S, Baud FJ. The role of insulin and glucose (hyperinsulinaemia/euglycaemia) therapy in acute calcium channel antagonist and beta-blocker poisoning. Toxicol Rev. 2004; 23: 215-222.




2020     |     www.medigraphic.com